Michael Winlo
Chief Scientific Officer at Emyria
Michael Winlo is co-founder and Chief Scientific Officer of Emyria, the ASX-listed mental health biotech, having stepped back from the chief executive role in 2025 to focus on the company's real-world evidence research, clinical trials and drug discovery programs for psychedelic-assisted therapies. He previously spent nine years as chief executive of Linear Clinical Research, Perth's dedicated early-phase clinical trial unit, and before that led the health team at Palantir Technologies in Silicon Valley. A medical doctor with an MBA from Stanford, he holds several data analysis patents. On What The Health, he discussed psychedelic medicine's shift from counterculture to clinical treatment.
Career
- Now Chief Scientific Officer · Emyria
- Until 2019 · Scale-up CEO · Linear Clinical Research
- Earlier · Scale-up Health Lead · Palantir Technologies
- Earlier · Startup Founding CEO · Cerulean Medical
Sources: rocketreach.co
Key moments
Jump straight to the part of The Psychedelic Resurgence: From Counterculture to Clinical Breakthrough with Dr Michael Winlo you want.
- 0:00 Psychedelics return to healthcare
- 0:57 What Emyria and the Empax clinics do
- 2:08 From medicine to Palantir and back to Perth
- 8:32 Why mental health care is falling behind
- 12:37 What psychedelics actually are
- 13:55 How MDMA-assisted therapy works
- 17:44 Psilocybin and the default mode network
- 21:05 A century of history: from Merck to the war on drugs
- 24:18 The revival: MAPS, new trials and Australia's rescheduling
- 27:17 Why psychiatry innovates slowly
Connections
Spot something wrong? Suggest a correction Updated 25 September 2026
Want a show of your own?
W2D1 Media — the team behind the Day One Network, which helped build Blackbird Ventures' Wild Hearts — builds and produces podcasts for funds, founders and operators. If you want a show built around your brand, let's talk.